SecBot SecBot
8-K ·Filed Aug 6, 2026

PEPG

PepGen Inc.
BULLISH
Impact 7/10
Horizonmonths Processed3mo ago SEC0001193125-26-336767
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The DSMB clearance to escalate to the highest dose cohort is a strong safety signal that de-risks the program. The November 10 mg/kg data readout is the next major catalyst; a positive readout could significantly re-rate the stock. Monitor for any updates on the FDA partial clinical hold, which remains a risk.

DirectionBullish
Confidencehigh
Horizonmonths

PGN-EDODM1

▲ Bullish Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
Next catalyst
None dated

What to watchWatch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$2.41
T+0 close · Aug 6, 2026 · via day close
Latest settled
−2.07%
T+60 · $2.36
Vs SPY
−0.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $2.41entry
  2. T+1 · 3mo ago +18.26%α +17.65% · $2.85
  3. T+5 · 3mo ago +23.65%α +22.44% · $2.98
  4. T+20 · 3mo ago +31.95%α +31.35% · $3.18
  5. T+60 · 18d ago −2.07%α −0.40% · $2.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus by 13.3%, with no revenue. The key catalyst is the DSMB's recommendation to advance PGN-EDODM1 into the highest 12.5 mg/kg dose cohort in the FREEDOM2-DM1 study and to dose-escalate the OLE, confirming a favorable safety profile. The company has $117.2M cash, sufficient into Q4 2027, and expects 10 mg/kg data in November 2026, which is the primary near-term catalyst.

Key Financial Metrics

EPS
−$0.26
est −$0.30 · +13.3%
Rating
beat

Key Facts

  • DSMB recommended advancing FREEDOM2 into the highest 12.5 mg/kg dose cohort with no protocol changes.
  • DSMB also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.
  • 10 mg/kg FREEDOM2 cohort fully enrolled; 7 of 8 participants completed dosing; data expected November 2026.
  • 12.5 mg/kg cohort results expected 1H 2027; EOP2 meeting with regulators planned thereafter.
  • Cash, cash equivalents and marketable securities were $117.2M as of June 30, 2026, sufficient into Q4 2027.
  • Net loss was $17.8M ($0.26 per share) vs $23.1M ($0.70 per share) in Q2 2025.
  • EPS of -$0.26 beat consensus of -$0.30 by 13.3%.
  • EMA granted Orphan Designation for PGN-EDODM1.
  • No serious adverse events or dose-limiting toxicities reported in FREEDOM2 or OLE to date.
  • 16 patients enrolled in FREEDOM-OLE at 5 mg/kg; 6 of 8 from 5 mg/kg FREEDOM2 cohort enrolled.

Financial Impact

EPS beat of 13.3% vs consensus; cash burn of ~$15.1M per quarter; cash runway extended into Q4 2027

epscashdilution

Risk Factors

  • FDA partial clinical hold on FREEDOM2 study remains unresolved.
  • 10 mg/kg data in November may not replicate the splicing correction trends seen at lower doses.
  • Dilution risk from potential future equity offerings to fund operations beyond current cash runway.
  • Clinical-stage biotech with no approved products or revenue; binary event risk around data readouts.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-336767
Document: pepg-20260806.htm0001193125-26-336767
Document: pepg-ex99_2.htm0001193125-26-336767
Document: pepg-ex99_3.htm0001193125-26-336767
Document: 0001193125-26-336767-index-headers.html0001193125-26-336767
Document: 0001193125-26-336767-index.html0001193125-26-336767
Document: 0001193125-26-336767.txt0001193125-26-336767
8-K Data (Synthetic)0001193125-26-336767

Track record

12 reports on PEPG

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +14.10% at T+1 after the Nov 10, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  2. Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
  3. Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
  4. Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
  5. Aug 6, 202614w ago 8-K Bullish 7/10 Viewing Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
  8. May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
  9. May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
  10. May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026